SABCS 2022 | Questions remaining in the field of HER2-low breast cancer

Clinton Yam, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses remaining questions in the field of HER2-low breast cancer, including whether HER2-low is a distinct entity. The differences observed between HER2-low and HER2-zero breast cancers may be driven by the difference in estrogen receptor (ER) expression. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.